However, ZP and EP (AKR1B1 inhibitors) showed a weak cytotoxic effect on all ovarian and breast cancer cell lines, especially on MCF7 and OVCAR3 cells, which a lack of AKR1B1. Here, AKR1B1 is linked to breast cancer.